| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-60019 | CTRPv2 | pan-cancer | AAC | 0.0064 | 0.9 |
| mRNA | CEP-701 | FIMM | pan-cancer | AAC | 0.021 | 0.9 |
| mRNA | A-804598 | CTRPv2 | pan-cancer | AAC | 0.0079 | 0.9 |
| mRNA | BRD-K33514849 | CTRPv2 | pan-cancer | AAC | -0.021 | 0.9 |
| mRNA | RO4929097 | CTRPv2 | pan-cancer | AAC | -0.0085 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | 0.0059 | 0.9 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |